Advertisement
INCY vs IONS
Which Stock Would AI Choose? Incyte Corporation (INCY) vs. Ionis Pharmaceuticals (IONS) Stock Comparison
Key Takeaways
- Incyte Corporation (INCY) trades around $91 with a market cap of approximately $18 billion, showing strong one-year returns near 49% but recent weakness after earnings miss on EPS despite revenue beat.
- Ionis Pharmaceuticals (IONS) hovers near $73 with a $12 billion market cap, boasting superior one-year gains over 130% driven by commercial launches like TRYNGOLZA and DAWNZERA.
- Both biotech firms focus on innovative therapies—INCY in oncology and inflammation via JAK inhibitors, IONS in RNA-targeted medicines—but IONS exhibits higher long-term momentum.
- Recent market activity reflects volatility: INCY down in recent weeks on post-earnings pressure, while IONS faces short-term dips amid broader sector sentiment.
- Analyst targets suggest upside for both, with IONS at ~$97 and INCY at ~$107, highlighting growth potential in their pipelines.
Introduction
Incyte Corporation (INCY) and Ionis Pharmaceuticals (IONS) represent key players in the biotechnology sector, focusing on specialized therapies for oncology, inflammatory diseases, and rare genetic disorders. This stock comparison evaluates their recent performance, business models, and market positioning amid evolving biotech trends. Traders seeking momentum plays may eye IONS's robust growth trajectory, while long-term investors might appreciate INCY's established revenue streams from products like JAKAFI. Understanding their relative strengths aids in assessing biotech stock opportunities in the current market environment.
INCY Overview and Recent Performance
Incyte Corporation (INCY), a biopharmaceutical firm, discovers, develops, and commercializes therapeutics targeting oncology and inflammation, with flagship products like JAKAFI (ruxolitinib) for myelofibrosis and polycythemia vera, and OPZELURA for atopic dermatitis. In recent market activity, INCY reported Q4 2025 revenue of $1.51 billion, up 27.8% year-over-year, beating estimates, though an EPS miss led to a stock pullback of about 17%. Positive data from its JAK1 inhibitor povorcitinib in hidradenitis suppurativa (HS), showing up to 71.4% clinical response rates in 54-week studies, has supported sentiment. Executive appointments aim to bolster R&D and commercialization. Year-to-date, shares are up modestly at around 8.55%, with a 52-week range of $53.56–$112.29 and P/E ratio of 14.09, reflecting profitability amid pipeline progress.
IONS Overview and Recent Performance
Ionis Pharmaceuticals (IONS), a pioneer in RNA-targeted medicines using antisense technology, markets products like TRYNGOLZA for familial chylomicronemia syndrome (FCS), DAWNZERA for hereditary angioedema, and WAINUA for ATTRv-PN (hereditary transthyretin-mediated amyloid polyneuropathy). Recent quarters showed 2025 full-year revenue of $944 million, up 34% year-over-year, fueled by TRYNGOLZA's $108 million launch-year sales. The FDA granted priority review for olezarsen in severe hypertriglyceridemia (sHTG), with potential approvals for multiple assets in 2026. Despite short-term declines, IONS delivered YTD gains near 8–9% and one-year returns exceeding 130%, within a 52-week range of $23.95–$86.74. Collaborations with Biogen, GSK, and others enhance its pipeline in neurology and cardiology.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds of bots that trade thousands of tickers across stocks, ETFs, and crypto. Only 25 bots earn a spot in this dynamic section, selected for their suitability to current market conditions, featuring diverse strategies like technical and fundamental analysis, varying timeframes (5min, 15min, 60min), and risk levels (low to high). Agents include real-time signal providers, virtual portfolio simulators with risk management, and brokerage-integrated options. These bots adapt to volatility, offering win rates and performance stats tailored to intermediate and expert users. Explore Tickeron’s full suite to identify bots aligning with your trading style and enhance decision-making in volatile markets like biotech.
Head-to-Head Comparison
Incyte (INCY) emphasizes commercial-stage oncology and immunology drugs, generating steady revenue from JAKAFI but facing patent cliffs, while Ionis (IONS) leverages antisense tech for rare diseases, prioritizing pipeline expansion via partnerships. Growth drivers differ: INCY benefits from Opzelura uptake and HS data; IONS from TRYNGOLZA momentum and olezarsen catalysts. Recent momentum favors IONS with superior one- and three-year returns (130%+ vs. 49%), though both show short-term softness. Risk profiles vary—INCY's beta of 0.84 signals lower volatility and positive net margins (25%); IONS (beta ~0.3–0.36) trades unprofitably but eyes multiple 2026 launches. Sector exposure aligns in biotech, but IONS sentiment rides regulatory wins, contrasting INCY's earnings volatility.
Tickeron AI Verdict
Tickeron’s AI models would likely favor Ionis Pharmaceuticals (IONS) in the current environment, given its trend consistency over one- and three-year periods, multiple near-term catalysts like olezarsen priority review, and higher analyst upside potential. While Incyte (INCY) offers stability and profitability, IONS's relative positioning in RNA therapeutics and commercial ramps suggests stronger probabilistic outperformance amid biotech recovery.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a StrongBuy and IONS is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 1 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).
- INCY’s FA Score: 1 green, 4 red.
- IONS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 4 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s).
- INCY’s TA Score: 4 bullish, 4 bearish.
- IONS’s TA Score: 4 bullish, 5 bearish.
Price Growth
INCY (@Biotechnology) experienced а +1.07% price change this week, while IONS (@Biotechnology) price change was +2.19% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.26%. For the same industry, the average monthly price growth was -2.98%, and the average quarterly price growth was +6.73%.
Reported Earning Dates
INCY is expected to report earnings on May 05, 2026.
IONS is expected to report earnings on May 06, 2026.
Industries' Descriptions
@Biotechnology (+2.26% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| INCY | IONS | INCY / IONS | |
| Capitalization | 19.3B | 12.6B | 153% |
| EBITDA | 1.76B | -273.12M | -644% |
| Gain YTD | -1.833 | -3.388 | 54% |
| P/E Ratio | 15.13 | N/A | - |
| Revenue | 5.14B | 944M | 545% |
| Total Cash | 3.58B | 2.68B | 134% |
| Total Debt | 40.4M | 2.07B | 2% |
INCY | IONS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 69 | 56 | |
SMR RATING 1..100 | 32 | 98 | |
PRICE GROWTH RATING 1..100 | 48 | 41 | |
P/E GROWTH RATING 1..100 | 100 | 72 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INCY's Valuation (70) in the Biotechnology industry is in the same range as IONS (100). This means that INCY’s stock grew similarly to IONS’s over the last 12 months.
IONS's Profit vs Risk Rating (56) in the Biotechnology industry is in the same range as INCY (69). This means that IONS’s stock grew similarly to INCY’s over the last 12 months.
INCY's SMR Rating (32) in the Biotechnology industry is significantly better than the same rating for IONS (98). This means that INCY’s stock grew significantly faster than IONS’s over the last 12 months.
IONS's Price Growth Rating (41) in the Biotechnology industry is in the same range as INCY (48). This means that IONS’s stock grew similarly to INCY’s over the last 12 months.
IONS's P/E Growth Rating (72) in the Biotechnology industry is in the same range as INCY (100). This means that IONS’s stock grew similarly to INCY’s over the last 12 months.
| INCY | IONS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 66% | 1 day ago 73% |
| Stochastic ODDS (%) | 1 day ago 59% | 1 day ago 69% |
| Momentum ODDS (%) | 1 day ago 62% | 1 day ago 69% |
| MACD ODDS (%) | 1 day ago 67% | 1 day ago 68% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 71% |
| TrendMonth ODDS (%) | 1 day ago 62% | 1 day ago 74% |
| Advances ODDS (%) | 1 day ago 61% | 1 day ago 67% |
| Declines ODDS (%) | 3 days ago 59% | 3 days ago 65% |
| BollingerBands ODDS (%) | 1 day ago 50% | 1 day ago 69% |
| Aroon ODDS (%) | 1 day ago 61% | 1 day ago 60% |
Advertisement
IONS and
Correlation & Price change
A.I.dvisor indicates that over the last year, IONS has been closely correlated with CYTK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if IONS jumps, then CYTK could also see price increases.
| Ticker / NAME | Correlation To IONS | 1D Price Change % | ||
|---|---|---|---|---|
| IONS | 100% | +1.93% | ||
| CYTK - IONS | 67% Closely correlated | -1.79% | ||
| MLYS - IONS | 66% Closely correlated | -2.13% | ||
| ARWR - IONS | 49% Loosely correlated | +2.92% | ||
| MNKD - IONS | 48% Loosely correlated | -1.53% | ||
| IDYA - IONS | 47% Loosely correlated | +0.13% | ||
More | ||||